# Resmed Inc: overview

RMD · NYSE · CIK 943819 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/rmd.md) · [Financials](/companies/rmd/financials.md) · [Filings](/companies/rmd/filings.md) · [Insiders](/companies/rmd/insiders.md)

Latest reported revenue: [$1.46bn](/filings/0000943819-26-000047.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000943819-26-000047).

## Last eight quarters

| Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,225](/filings/0000943819-25-000090.md) | [1,282](/filings/0000943819-26-000007.md) | [1,292](/filings/0000943819-26-000025.md) | [1,348 d](/filings/0000943819-26-000047.md) | [1,336](/filings/0000943819-25-000090.md) | [1,423](/filings/0000943819-26-000007.md) | [1,431](/filings/0000943819-26-000025.md) | [1,464 d](/filings/0000943819-26-000047.md) |
| Gross margin | % | [58.6%](/filings/0000943819-25-000090.md) | [58.6%](/filings/0000943819-26-000007.md) | [59.3%](/filings/0000943819-26-000025.md) | [60.8% d](/filings/0000943819-26-000047.md) | [61.5%](/filings/0000943819-25-000090.md) | [61.8%](/filings/0000943819-26-000007.md) | [62.2%](/filings/0000943819-26-000025.md) | [58.8% d](/filings/0000943819-26-000047.md) |
| Operating margin | % | [31.6%](/filings/0000943819-25-000090.md) | [32.5%](/filings/0000943819-26-000007.md) | [33.0%](/filings/0000943819-26-000025.md) | [33.7% d](/filings/0000943819-26-000047.md) | [33.4%](/filings/0000943819-25-000090.md) | [34.6%](/filings/0000943819-26-000007.md) | [34.9%](/filings/0000943819-26-000025.md) | [30.7% d](/filings/0000943819-26-000047.md) |
| Net margin | % | [25.4%](/filings/0000943819-26-000025.md) | [26.9%](/filings/0000943819-26-000025.md) | [28.3%](/filings/0000943819-26-000025.md) | [28.2% d](/filings/0000943819-26-000047.md) | [26.1%](/filings/0000943819-26-000025.md) | [27.6%](/filings/0000943819-26-000025.md) | [27.9%](/filings/0000943819-26-000025.md) | [26.2% d](/filings/0000943819-26-000047.md) |
| Diluted EPS | $ per share | [2.11](/filings/0000943819-25-000090.md) | [2.34](/filings/0000943819-26-000007.md) | [2.48](/filings/0000943819-26-000025.md) | not reported | [2.37](/filings/0000943819-25-000090.md) | [2.68](/filings/0000943819-26-000007.md) | [2.74](/filings/0000943819-26-000025.md) | not reported |
| Free cash flow | $m | [308](/filings/0000943819-25-000090.md) | [288 d](/filings/0000943819-26-000007.md) | [558 d](/filings/0000943819-26-000025.md) | [508 d](/filings/0000943819-26-000047.md) | [414](/filings/0000943819-25-000090.md) | [311 d](/filings/0000943819-26-000007.md) | [520 d](/filings/0000943819-26-000025.md) | [404 d](/filings/0000943819-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,578](/filings/0000943819-24-000013.md) | [4,223](/filings/0000943819-25-000035.md) | [4,685](/filings/0000943819-26-000047.md) | [5,146](/filings/0000943819-26-000047.md) | [5,653](/filings/0000943819-26-000047.md) |
| Gross margin | % | [56.6%](/filings/0000943819-24-000013.md) | [55.8%](/filings/0000943819-25-000035.md) | [56.7%](/filings/0000943819-26-000047.md) | [59.4%](/filings/0000943819-26-000047.md) | [61.1%](/filings/0000943819-26-000047.md) |
| Operating margin | % | [28.0%](/filings/0000943819-24-000013.md) | [26.8%](/filings/0000943819-25-000035.md) | [28.2%](/filings/0000943819-26-000047.md) | [32.7%](/filings/0000943819-26-000047.md) | [33.4%](/filings/0000943819-26-000047.md) |
| Net margin | % | [21.8%](/filings/0000943819-24-000013.md) | [21.3%](/filings/0000943819-25-000035.md) | [21.8%](/filings/0000943819-26-000047.md) | [27.2%](/filings/0000943819-26-000047.md) | [26.9%](/filings/0000943819-26-000047.md) |
| Diluted EPS | $ per share | [5.30](/filings/0000943819-24-000013.md) | [6.09](/filings/0000943819-25-000035.md) | [6.92](/filings/0000943819-26-000047.md) | [9.51](/filings/0000943819-26-000047.md) | [10.43](/filings/0000943819-26-000047.md) |
| Free cash flow | $m | [216](/filings/0000943819-24-000013.md) | [574](/filings/0000943819-25-000035.md) | [1,302](/filings/0000943819-26-000047.md) | [1,662](/filings/0000943819-26-000047.md) | [1,650](/filings/0000943819-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rmd/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-23 | [Rider Michael J](/insiders/1982205.md) | Global General Counsel, Officer | Sale (S) | 400 | $255.00 | $102.0k | [Form 4](/filings/0000943819-26-000086.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.40bn | 12,317,194 |  | Added +223,171 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.85bn | 9,474,129 |  | Added +7,713 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.54bn | 7,913,661 |  | Added +49,739 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.30bn | 6,680,735 |  | Added +37,567 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $845.2m | 4,352,320 |  | Reduced −553 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $818.0m | 4,197,610 |  | Reduced −727,776 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $444.1m | 2,278,696 |  | Added +740,871 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $402.1m | 2,063,578 |  | Added +106,964 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $375.9m | 1,928,931 |  | Reduced −757,890 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $330.6m | 1,696,674 |  | Reduced −29,019 |

## Recent filings

[All 1,915 filings](/companies/rmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:05 ET | [8-K](/filings/0001193125-26-437783.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-437783 |
| 2026-10-01 | 16:34 ET | [DEF 14A](/filings/0000943819-26-000080.md) | Proxy statement, period 2026-06-30 | 0000943819-26-000080 |
| 2026-09-01 | 16:30 ET | [8-K](/filings/0001193125-26-378487.md) | 8.01 Other events | 0001193125-26-378487 |
| 2026-08-17 | 16:30 ET | [8-K](/filings/0001193125-26-354154.md) | 4.01 Change of auditor; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354154 |
| 2026-08-13 | 17:17 ET | [10-K](/filings/0000943819-26-000047.md) | Annual report, period 2026-06-30 | 0000943819-26-000047 |
| 2026-08-06 | 16:05 ET | [8-K](/filings/0001193125-26-337962.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-337962 |
| 2026-07-07 | 17:24 ET | [8-K](/filings/0001193125-26-297658.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-297658 |
| 2026-05-01 | 18:19 ET | [10-Q](/filings/0000943819-26-000025.md) | Quarterly report, period 2026-03-31 | 0000943819-26-000025 |
| 2026-04-30 | 16:10 ET | [8-K](/filings/0001193125-26-197282.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-197282 |
| 2026-04-30 | 16:06 ET | [8-K](/filings/0001193125-26-197192.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-197192 |

## Latest annual report

[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0000943819-26-000047.md), filed Aug 13, 2026.

## Forecast league

Q1 FY2027, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/968f3d95-ca21-4458-8658-197d92d919d0)

## About the filer

- CIK: 943819
- Tickers: RMD, RSMDF
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:07 ET. No prices; not investment advice.